Neck surgery carries a risk that the patient will develop postoperative thy roiditis as a result ofthe surgical procedure. Surge ry-induced thyroiditi s can manifest in a mild f orm as se rum hyp erthyroxinemia or in a more severe form as clini cal hyperthyroidi sm. We describe a case of surge ry-induced thyroid itis and revi ew the very limit ed literature on this subject.
Introduction
In 1975, Carne y et al suggested that traum a to the thyroid might be a significant etiolo gic factor in the development of some cases of thyroiditis.I Since then, howeve r, very few clinical data have been publi shed to support this suggestion. In this article, we describ e a case of transient thyroiditis following a total laryngectomy.
Case repo rt
A 76-year-old man , a count ry-and-w estern singer, came to the ENT department with a 2-year history of dysphonia. He was a physically fit nonsmoker, and he had no personal or family history of thyroid disease. Clin ical examination, direct laryngoscopy , and biopsy revealed the presence of a subglottic tumor, which was stage d as T2NOMO. Histopathol ogic analysis of the biopsy specimen identified it as a well-differentiated squamous carcinoma. The result s of preoperative hem atolo gic and biochemical tests, including those of thyroid function, were within normal parameters. Findin gs on ultrasonography of the thyroid and comput ed tomography (CT) of the neck and chest were entirely normal.
The patient unde rwent a total laryn gectomy with preservation of the thyroid. The surgic al procedure was uneventful, and over the follow ing 24 hours, the patient During the follo wing week, the patient was noted to have rising levels of serum free thyroxine (T 4 ) and triiodothyronine (T)) and a correspond ing reduction in the level of serum thyroid-stimulating hormone (TSH) (figure). Antith yroid antibodies were not detected.
A diagnosis of postoperative thyroiditis was made, and the patient was started on an intravenous beta blocker and carbim azole , a thionamide medication used in the treatment of hyperth yroidism. His condition normali zed over the following week, and on postoperative day 15, all , medication was withdrawn. He made a complete recovery and had no clinical or biochemical signs of thyroid disease. A definitive diagnosis of transient thyroiditis secondary to surgical manipulation was made.
Discussion
Preoperatively, our patient was both clinically and biochemically euthyroid , which rules out the possibility that he had had pre-exi sting, undiagnosed hype rthyroidism. Also, his initial serum T 4 and TSH levels 24 hours postoperativel y were within normal limits, which excludes the hypothesis that his hyperthyroidism was the result of an intraoperative surge of T, release. Forty-eight hour s postoperatively, his condition was consistent with thyrotoxicosis.
The exact cause of this patient' s postoperati ve hyperthyroidism is unclear. We speculate that it was likely the result of vigorous manipulation of the thyroid during surgery. Such manipulation could have induced an acute thyroiditis, which in turn might have led to a sustained release of T 4 over a prolonged period-in this case, 15 days. 
For Extemporaneous Preparation of Oral Suspension

Have your patients swish-and-swallow the sensible sugar-free way
Large oral doses occassionally produced diarrhea, GI distress, and possible irritation ofthe stomach that may cause nausea and vomiting. The sparse ness of reported cases of postoperative transient thyroto xicosis in the world literature might well reflect the fact that they are mild and unrecognized; in order to be identified, such thyroiditis would have to be clinically severe enough to manifest as hyperthyroidi sm rather than as j ust an increa se in serum T 4 • We therefore recommend that any patient who deve lop s an unexplained tachycardia or tachyarrhythmia following neck surgery shou ld undergo urge nt thyroid function tes ting to excl ude surgery-induced thyroidi tis. Nystatin USP is an antifungal antibiotic obtained from Streptomyces noursei. It is known to be a mixture, b e com position has not been completely elucidated. Nystatin A is closely relatedtoamphotericinB. Each is a macrocyclic lactone containingaketal ring, an all-trans polyene system,and a mycosamine (3-amino-3-deoxy-rhamnose) moiety. NystatinA has a molecul ar tormula of C47H7SN017 and a molecular weight of 926. 11.
OH
NystatinA
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